LONDON, Sept 21 (Reuters) - AstraZeneca has pulledan application seeking European approval to sell itsexperimental cancer drug cediranib in combination withchemotherapy to treat ovarian cancer because of late-stagequestions raised by regulators reviewing the product.
However, the British company said on Wednesday thatcediranib, a so-called VEGFR inhibitor, remained an importantpipeline medicine and the decision did not affect its ongoingdevelopment in combination tests alongside other drugs. (Reporting by Ben Hirschler; editing by Jason Neely)
Astrazeneca (AZN)